Scott Kathleen D.
Director at DRMA; Chief Financial Officer at SPRY
- Sold, on record
- $1.3M
- Dollars the filings state
- Form 4 sales
- 5
- Latest Jun 16, 2026
- Form 144 notices
- 4
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
Sales by reason
3
Routine
0
Plan not stated
0
No plan
2
Unusual
Form 4 sales per month, every sale on record.
Sales by company
Shares sold, every Form 4 sale on record.
Timeline
- Jun 16, 2026Unusual
Sold 100% of their holdings
$1311 shares at $1.19
- Aug 21, 2025Routine
Sold 55.5% of their holdings
$188k12,500 shares at $15.00
- Aug 21, 2025Notice
Filed a notice to sell 12,500 shares
$188k12,500 shares
- May 20, 2025Unusual
Sold 87.1% of their holdings
$705k50,000 shares at $14.10
- May 20, 2025Notice
Filed a notice to sell 50,000 shares
$705k50,000 shares
- Oct 16, 2024Routine
Sold 71.6% of their holdings
$200k12,500 shares at $16.00
- Oct 16, 2024Notice
Filed a notice to sell 12,500 shares
$200k12,500 shares
- Aug 20, 2024Routine
Sold 48.6% of their holdings
$200k12,500 shares at $16.00
- Aug 20, 2024Notice
Filed a notice to sell 12,500 shares
$200k12,500 shares
9 of 9
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Jun 16, 2026 | DRMA | Director | Sold | 11 | $1.19 | $13 | 0 | SEC |
| Jan 2, 2026 | Jan 5, 2026 | SPRY | Chief Financial Officer | AwardedStock option (right to buy) | 240,000 | 240,000 | SEC | ||
| Jan 2, 2026 | Jan 6, 2026 | DRMA | Director | AwardedStock Option (Right to Buy) | 2,500 | 2,500 | SEC | ||
| Aug 21, 2025 | Aug 22, 2025 | SPRY | Chief Financial Officer | Sold | 12,500 | $15.00 | $188k | 10,042 | SEC |
| Aug 21, 2025 | Aug 22, 2025 | SPRY | Chief Financial Officer | Exercised or settledStock Option (Right to Buy) | 12,500 | 739,830 | SEC | ||
| Aug 21, 2025 | Aug 22, 2025 | SPRY | Chief Financial Officer | Exercised options | 12,500 | $1.50 | $19k | 22,542 | SEC |
| May 20, 2025 | May 22, 2025 | SPRY | Chief Financial Officer | Sold | 50,000 | $14.10 | $705k | 7,424 | SEC |
| May 20, 2025 | May 22, 2025 | SPRY | Chief Financial Officer | Exercised or settledStock Option (Right to Buy) | 50,000 | 752,330 | SEC | ||
| May 20, 2025 | May 22, 2025 | SPRY | Chief Financial Officer | Exercised options | 50,000 | $1.50 | $75k | 57,424 | SEC |
| Jan 13, 2025 | Jan 14, 2025 | DRMA | Director | AwardedStock Option (Right to Buy) | 5,000 | 5,000 | SEC | ||
| Jan 2, 2025 | Jan 3, 2025 | SPRY | Chief Financial Officer | AwardedStock option (right to buy) | 176,700 | 176,700 | SEC | ||
| Dec 6, 2024 | Dec 10, 2024 | NKGN | Director | AwardedStock Option (right to buy) | 800,000 | 500,000 | SEC | ||
| Oct 16, 2024 | Oct 17, 2024 | SPRY | Chief Financial Officer | Sold | 12,500 | $16.00 | $200k | 4,949 | SEC |
| Oct 16, 2024 | Oct 17, 2024 | SPRY | Chief Financial Officer | Exercised or settledStock Option (Right to Buy) | 12,500 | 802,330 | SEC | ||
| Oct 16, 2024 | Oct 17, 2024 | SPRY | Chief Financial Officer | Exercised options | 12,500 | $1.50 | $19k | 17,449 | SEC |
| Aug 20, 2024 | Aug 21, 2024 | SPRY | Chief Financial Officer | Sold | 12,500 | $16.00 | $200k | 13,199 | SEC |
| Aug 20, 2024 | Aug 21, 2024 | SPRY | Chief Financial Officer | Exercised or settledStock Option (Right to Buy) | 12,500 | 814,830 | SEC | ||
| Aug 20, 2024 | Aug 21, 2024 | SPRY | Chief Financial Officer | Exercised options | 12,500 | $1.50 | $19k | 25,699 | SEC |
| Feb 12, 2024 | Feb 14, 2024 | NKGN | Director | AwardedStock Option (right to buy) | 300,000 | 300,000 | SEC | ||
| Jan 4, 2024 | Jan 5, 2024 | DRMA | Director | AwardedStock Option (Right to Buy) | 10,000 | 10,000 | SEC | ||
| Jan 2, 2024 | Jan 4, 2024 | SPRY | Chief Financial Officer | AwardedStock option (right to buy) | 200,000 | 200,000 | SEC | ||
| Jan 3, 2023 | Jan 5, 2023 | SPRY | Chief Financial Officer | AwardedStock option (right to buy) | 50,000 | 50,000 | SEC | ||
| Nov 29, 2022 | Dec 1, 2022 | SPRY | Chief Financial Officer | Bought | 8,250 | $6.24 | $51k | 8,250 | SEC |
| Nov 8, 2022 | Nov 10, 2022 | SPRY | Chief Financial Officer | AwardedEmployee Stock Option (right to buy) | 827,330 | 827,330 | SEC | ||
| Oct 6, 2022 | Oct 7, 2022 | DRMA | Director | Awarded | 11,359 | 27,145 | SEC | ||
| Jul 7, 2022 | Jul 8, 2022 | DRMA | Director | Awarded | 9,960 | 15,786 | SEC | ||
| Apr 7, 2022 | Apr 8, 2022 | DRMA | Director | Awarded | 5,826 | 5,826 | SEC | ||
| Jan 3, 2022 | Jan 5, 2022 | DRMA | Director | AwardedStock Option (right to buy) | 5,000 | 5,000 | SEC | ||
| Aug 17, 2021 | Aug 17, 2021 | DRMA | Director | AwardedStock Option (right to Buy) | 10,000 | 10,000 | SEC | ||
| Nov 18, 2019 | Nov 19, 2019 | Conatus Pharmaceuticals Inc | Director | AwardedStock Option (Right to Buy) | 30,000 | 30,000 | SEC |
Sales and notices (9)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Jun 16, 2026 | DRMA | Director | Form 4 sale | 11 | $13 | 100.0% | Unusual | SEC |
| Aug 21, 2025 | Aug 22, 2025 | SPRY | Chief Financial Officer | Form 4 sale | 12,500 | $188k | 55.5% | Routine | SEC |
| Aug 21, 2025 | Aug 21, 2025 | SPRY | Chief Financial Officer | Form 144 notice | 12,500 | $188k | Notice | SEC | |
| May 20, 2025 | May 22, 2025 | SPRY | Chief Financial Officer | Form 4 sale | 50,000 | $705k | 87.1% | Unusual | SEC |
| May 20, 2025 | May 20, 2025 | SPRY | Chief Financial Officer | Form 144 notice | 50,000 | $705k | Notice | SEC | |
| Oct 16, 2024 | Oct 17, 2024 | SPRY | Chief Financial Officer | Form 4 sale | 12,500 | $200k | 71.6% | Routine | SEC |
| Oct 16, 2024 | Oct 16, 2024 | SPRY | Chief Financial Officer | Form 144 notice | 12,500 | $200k | Notice | SEC | |
| Aug 20, 2024 | Aug 21, 2024 | SPRY | Chief Financial Officer | Form 4 sale | 12,500 | $200k | 48.6% | Routine | SEC |
| Aug 20, 2024 | Aug 20, 2024 | SPRY | Chief Financial Officer | Form 144 notice | 12,500 | $200k | Notice | SEC |